The Cigna Group
CI
$287.66
-2.97%
The Cigna Group is a global health services company that provides pharmacy benefit management (PBM) through its Evernorth segment and health insurance through its Cigna Healthcare segment. As one of the largest PBMs in the U.S., Cigna holds a strong competitive position, particularly after its 2018 merger with Express Scripts, and serves a diverse client base including employers, health plans, and government entities. The current investor narrative centers on Cigna's ability to sustain margin expansion and revenue growth amid a strategic pivot, as evidenced by its recent decision to exit individual exchange markets and review its eviCore business, while raising its full-year outlook. This focus on core operations and capital deployment has driven debate around the stock's risk-reward profile.…
CI
The Cigna Group
$287.66
Related headlines
CI 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on The Cigna Group's 12-month outlook, with a consensus price target around $340.92 and implied upside of +18.5% versus the current price.
Average Target
$340.92
0 analysts
Implied Upside
+18.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$290 - $400
Analyst target range
Cigna is covered by 24 analysts, with a consensus recommendation of 'Buy' (mean rating 1.54 on a 1-5 scale where 1 is Strong Buy). The average target price is $340.92, implying approximately 17.7% upside from the current price of $289.57. The distribution leans heavily bullish, with no sell ratings and a strong buy/hold mix. This consensus reflects confidence in Cigna's earnings trajectory and strategic direction. The target price range spans from a low of $290.00 to a high of $400.00. The high target of $400 assumes significant multiple expansion and accelerating growth, likely driven by successful execution of the PBM business and cost synergies. The low target of $290 is just above the current price, suggesting minimal downside risk but limited upside in a bear case. Recent ratings actions show a mix of reaffirmations and a few downgrades (e.g., Barclays from Overweight to Equal Weight, Deutsche Bank from Buy to Hold), indicating some caution. The wide spread between low and high targets ($110) signals high uncertainty about the stock's future performance, but the overall bullish consensus provides a supportive backdrop.
Drowning in data?
Find the real signal!
Bulls vs Bears: CI Investment Factors
Cigna presents a compelling value proposition with a forward P/E of 8.65x, a 52% discount to the sector average, and strong free cash flow generation of $7.66 billion. The bullish case is supported by a consensus Buy rating, 17.7% upside to the average analyst target, and improving margins. However, bears point to a low net margin of 2.41%, strategic execution risks from exiting individual exchanges, and recent analyst downgrades. The central tension is whether Cigna's low valuation is a value trap or an opportunity: the market is pricing in skepticism about earnings sustainability, but if the company delivers on its raised outlook and margin expansion, the stock could re-rate significantly. Currently, the evidence slightly favors the bulls given the strong free cash flow and analyst support, but the narrow net margin and strategic uncertainty warrant caution.
Bullish
- Attractive forward P/E discount: Cigna's forward P/E of 8.65x is a 52% discount to the sector average of ~18x, and well below its own historical range. This implies significant earnings growth expectations and offers a compelling entry point if the company delivers on its raised outlook.
- Strong free cash flow generation: Cigna generated $7.66 billion in free cash flow over the trailing twelve months, representing a free cash flow yield of approximately 10.5% relative to its market cap. This robust cash generation supports shareholder returns and provides a margin of safety.
- Consensus analyst buy rating: With 24 analysts covering the stock, the consensus is a Buy (mean rating 1.54/5) and an average target price of $340.92, implying 17.7% upside from the current price of $289.57. No sell ratings exist, reflecting broad confidence in the company's strategy.
- Revenue growth and margin expansion: Q1 2026 revenue grew 4.57% YoY to $68.49 billion, while operating margin improved to 3.44% from 2.96% in Q4 2025. The company also raised its full-year outlook, signaling confidence in sustained operational improvement.
Bearish
- Low net margin relative to peers: Cigna's net margin of 2.41% is below the industry average, partly due to the high-revenue, low-margin PBM business. This structural margin constraint limits earnings growth potential and justifies some valuation discount.
- Strategic pivot introduces execution risk: Cigna's decision to exit individual exchange markets and review its eviCore business creates near-term uncertainty. While these moves may streamline operations, they also risk revenue disruption and distract management from core growth.
- Recent analyst downgrades signal caution: Barclays downgraded Cigna from Overweight to Equal Weight, and Deutsche Bank from Buy to Hold. These downgrades suggest that some analysts see limited upside or increased risk, tempering the otherwise bullish consensus.
- Low beta may limit upside in bull markets: With a beta of 0.30, Cigna is significantly less volatile than the market. While this reduces downside risk, it also means the stock may underperform during strong market rallies, as seen in its -17.95% relative strength versus the S&P 500 over the past year.
CI Technical Analysis
Cigna's stock is in a mild recovery trend after a volatile year, with a 1-year price change of -1.48% reflecting a slight decline. The current price of $289.57 sits at 50.3% of its 52-week range ($239.51 to $315.47), indicating it is roughly in the middle of the range—neither overextended nor deeply undervalued. This positioning suggests a neutral technical posture, with the stock having recovered from its lows but still below its highs, implying potential for further upside if momentum builds. Over the past 3 months, the stock has gained 5.05%, while the 1-month return is 3.62%, showing accelerating short-term momentum. However, the 1-year decline contrasts with this recent strength, creating a divergence that could signal a potential trend reversal or a temporary rally within a broader downtrend. The relative strength versus the S&P 500 is positive over 1-month (2.84%) but negative over 1-year (-17.95%), confirming that recent outperformance is a short-term phenomenon. Key support lies at the 52-week low of $239.51, a breakdown below which would signal a bearish continuation. Resistance is at the 52-week high of $315.47; a breakout above this level would indicate a strong uptrend resumption. With a beta of 0.30, Cigna is significantly less volatile than the market, meaning it tends to move less than the S&P 500, which can be attractive for risk-averse investors but may lag in strong bull markets.
Beta
0.30
0.30x market volatility
Max Drawdown
-26.9%
Largest decline past year
52-Week Range
$240-$315
Price range past year
Annual Return
-3.4%
Cumulative gain past year
| Period | CI Return | S&P 500 |
|---|---|---|
| 1m | +4.3% | -0.7% |
| 3m | +1.7% | +2.9% |
| 6m | +4.9% | +7.2% |
| 1y | -3.4% | +16.9% |
| ytd | +3.1% | +8.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CI Fundamental Analysis
Cigna's revenue trajectory remains solidly growing, with Q1 2026 revenue of $68.49 billion, up 4.57% year-over-year from $65.50 billion in Q1 2025. The growth is driven by its Evernorth segment ($58.44 billion in Q1 2026) which accounts for the bulk of revenue, while Cigna Healthcare contributed $11.48 billion. The multi-quarter trend shows consistent sequential growth, with revenue accelerating from $65.50B in Q1 2025 to $68.49B in Q1 2026, indicating a healthy top-line trajectory. This growth supports the investment case as it demonstrates the company's ability to expand its PBM and health insurance businesses. Profitability is robust, with net income of $1.65 billion in Q1 2026 and a net margin of 2.41%. Gross margin improved to 9.45% in Q1 2026 from 7.66% in Q4 2025, though it remains below the 11.73% seen in Q2 2025. Operating margin was 3.44% in Q1 2026, up from 2.96% in Q4 2025, indicating margin expansion. The company is consistently profitable, and margins are stable to improving, which is positive for the investment thesis. Cigna's balance sheet is healthy, with a debt-to-equity ratio of 0.75 and a current ratio of 0.85, indicating manageable leverage and adequate liquidity. Free cash flow (TTM) is $7.66 billion, providing strong cash generation to fund operations and shareholder returns. Return on equity (ROE) stands at 14.28%, reflecting efficient capital use. The company's free cash flow yield (FCF/Price) is approximately 10.5%, suggesting the stock is reasonably valued relative to cash generation. Overall, Cigna's financial health is solid, with sufficient internal cash flow to support growth and dividends.
Quarterly Revenue
$68.5B
2026-03
Revenue YoY Growth
+4.6%
YoY Comparison
Gross Margin
9.4%
Latest Quarter
Free Cash Flow
$7.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CI Overvalued?
Since Cigna has positive net income, the primary valuation metric is the P/E ratio. The trailing P/E is 12.34x, while the forward P/E is 8.65x, a significant discount that implies the market expects earnings growth. The gap between trailing and forward P/E suggests that analysts anticipate a sharp increase in earnings, which is consistent with the company's raised outlook. Compared to the industry average (Medical - Healthcare Plans), Cigna's trailing P/E of 12.34x is well below the sector average of approximately 18x, representing a 31% discount. This discount may be justified by Cigna's lower net margin (2.41%) versus some peers, but its strong free cash flow and growth prospects argue that the discount is excessive. Historically, Cigna's trailing P/E has ranged from about 7.6x (Q3 2022) to 32.7x (Q3 2024), with the current 12.34x near the lower end of its historical band. This suggests the stock is trading at a relatively cheap valuation compared to its own history, which could indicate a value opportunity if fundamentals remain strong. However, the low P/E also reflects market skepticism about the sustainability of earnings growth, given the company's strategic shifts.
PE
12.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 10x~17x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
8.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Cigna's debt-to-equity ratio of 0.75 is manageable, but its current ratio of 0.85 indicates that current liabilities exceed current assets, which could pose liquidity risk in a downturn. The company's net margin of 2.41% is thin, leaving little room for error if costs rise or revenue growth stalls. Additionally, the PBM business, which generates the bulk of revenue, is capital-light but faces regulatory and pricing pressure that could compress margins further. Free cash flow of $7.66 billion provides a buffer, but any disruption to the DoD contract or Centene deal could materially impact earnings.
Market & Competitive Risks: Cigna's trailing P/E of 12.34x is well below its historical average, but this discount may persist if the market remains skeptical about the sustainability of its earnings growth. The stock's low beta of 0.30 means it is less correlated with the market, but it also underperformed the S&P 500 by 17.95% over the past year, indicating that investors have been rotating away from managed care stocks. Competitive threats include other large PBMs like CVS Caremark and OptumRx, which could pressure pricing. Regulatory headwinds, such as potential PBM reform legislation, could also disrupt Cigna's business model.
Worst-Case Scenario: In a severe downturn, Cigna could face a combination of PBM pricing pressure, loss of key contracts, and margin compression, leading to earnings disappointment. The 52-week low of $239.51 represents a 17.3% decline from the current price of $289.57. If the company were to cut guidance or face a regulatory setback, the stock could fall to that level or lower. Historically, the maximum drawdown has been 26.91%, which would imply a price of approximately $211.50. In such a scenario, an investor could lose up to 27% from the current price.
